Takara Bio Inc. (4974.T)
JPY 1002.0
(-0.2%)
JPY 1002.0
(-0.2%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 968 Million JPY | -0.41% |
| 2022 | 972 Million JPY | -7.16% |
| 2021 | 1.04 Billion JPY | -8.24% |
| 2020 | 1.14 Billion JPY | 1.88% |
| 2019 | 1.12 Billion JPY | 0.0% |
| 2018 | - JPY | 0.0% |
| 2017 | - JPY | -100.0% |
| 2016 | 129 Million JPY | -33.16% |
| 2015 | 193 Million JPY | -17.87% |
| 2014 | 235 Million JPY | -34.9% |
| 2013 | 361 Million JPY | 1.4% |
| 2012 | 356 Million JPY | -9.41% |
| 2011 | 393 Million JPY | -3.91% |
| 2010 | 409 Million JPY | -10.11% |
| 2009 | 455 Million JPY | -9.0% |
| 2008 | 500 Million JPY | -8.26% |
| 2007 | 545 Million JPY | -7.63% |
| 2006 | 590 Million JPY | -6.94% |
| 2005 | 634 Million JPY | -56.34% |
| 2004 | 1.45 Billion JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - JPY | -100.0% |
| 2023 Q1 | 1.17 Billion JPY | 20.47% |
| 2023 FY | 968 Million JPY | -0.41% |
| 2023 Q3 | 1.17 Billion JPY | -0.42% |
| 2023 Q4 | 968 Million JPY | -17.41% |
| 2023 Q2 | 1.17 Billion JPY | 0.51% |
| 2022 Q4 | 972 Million JPY | -39.63% |
| 2022 Q2 | 1.79 Billion JPY | 20.94% |
| 2022 Q1 | 1.48 Billion JPY | 41.83% |
| 2022 FY | 972 Million JPY | -7.16% |
| 2022 Q3 | 1.61 Billion JPY | -10.36% |
| 2021 Q1 | 1.45 Billion JPY | 27.61% |
| 2021 Q2 | 1.44 Billion JPY | -0.55% |
| 2021 Q3 | 1.41 Billion JPY | -2.07% |
| 2021 FY | 1.04 Billion JPY | -8.24% |
| 2021 Q4 | 1.04 Billion JPY | -26.16% |
| 2020 Q3 | - JPY | 0.0% |
| 2020 Q2 | - JPY | 0.0% |
| 2020 FY | 1.14 Billion JPY | 1.88% |
| 2020 Q1 | - JPY | -100.0% |
| 2020 Q4 | 1.14 Billion JPY | 0.0% |
| 2019 Q4 | 1.12 Billion JPY | 0.0% |
| 2019 Q3 | - JPY | 0.0% |
| 2019 FY | 1.12 Billion JPY | 0.0% |
| 2019 Q2 | - JPY | 0.0% |
| 2019 Q1 | - JPY | 0.0% |
| 2018 Q4 | - JPY | 0.0% |
| 2018 Q3 | - JPY | 0.0% |
| 2018 FY | - JPY | 0.0% |
| 2018 Q2 | - JPY | 0.0% |
| 2018 Q1 | - JPY | 0.0% |
| 2017 Q3 | 115 Million JPY | -82.31% |
| 2017 Q2 | 650 Million JPY | 1.09% |
| 2017 Q1 | 643 Million JPY | 398.45% |
| 2017 FY | - JPY | -100.0% |
| 2017 Q4 | - JPY | -100.0% |
| 2016 Q2 | 163 Million JPY | -12.83% |
| 2016 Q3 | 163 Million JPY | 0.0% |
| 2016 FY | 129 Million JPY | -33.16% |
| 2016 Q1 | 187 Million JPY | -3.11% |
| 2016 Q4 | 129 Million JPY | -20.86% |
| 2015 Q3 | 211 Million JPY | 0.0% |
| 2015 Q1 | 225 Million JPY | -4.26% |
| 2015 FY | 193 Million JPY | -17.87% |
| 2015 Q2 | 211 Million JPY | -6.22% |
| 2015 Q4 | 193 Million JPY | -8.53% |
| 2014 Q3 | 353 Million JPY | 1.44% |
| 2014 Q2 | 348 Million JPY | -3.6% |
| 2014 Q1 | 361 Million JPY | 0.0% |
| 2014 Q4 | 235 Million JPY | -33.43% |
| 2014 FY | 235 Million JPY | -34.9% |
| 2013 FY | 361 Million JPY | 1.4% |
| 2013 Q2 | 332 Million JPY | -7.52% |
| 2013 Q1 | 359 Million JPY | 0.84% |
| 2013 Q4 | 361 Million JPY | 7.12% |
| 2013 Q3 | 337 Million JPY | 1.51% |
| 2012 Q3 | 385 Million JPY | 2.67% |
| 2012 Q1 | 396 Million JPY | 0.76% |
| 2012 Q2 | 375 Million JPY | -5.3% |
| 2012 Q4 | 356 Million JPY | -7.53% |
| 2012 FY | 356 Million JPY | -9.41% |
| 2011 Q3 | 395 Million JPY | 0.0% |
| 2011 Q4 | 393 Million JPY | -0.51% |
| 2011 Q1 | 409 Million JPY | 0.0% |
| 2011 FY | 393 Million JPY | -3.91% |
| 2011 Q2 | 395 Million JPY | -3.42% |
| 2010 Q2 | 441 Million JPY | -3.08% |
| 2010 Q4 | 409 Million JPY | -7.26% |
| 2010 Q3 | 441 Million JPY | 0.0% |
| 2010 Q1 | 455 Million JPY | 0.0% |
| 2010 FY | 409 Million JPY | -10.11% |
| 2009 Q3 | 486 Million JPY | 0.0% |
| 2009 FY | 455 Million JPY | -9.0% |
| 2009 Q4 | 455 Million JPY | -6.38% |
| 2009 Q2 | 486 Million JPY | 0.0% |
| 2008 Q4 | 500 Million JPY | 0.0% |
| 2008 FY | 500 Million JPY | -8.26% |
| 2007 FY | 545 Million JPY | -7.63% |
| 2006 FY | 590 Million JPY | -6.94% |
| 2005 FY | 634 Million JPY | -56.34% |
| 2004 FY | 1.45 Billion JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 2.46 Billion JPY | 60.805% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 3.69 Billion JPY | 73.834% |
| Linical Co., Ltd. | 3 Billion JPY | 67.754% |
| Trans Genic Inc. | 2.25 Billion JPY | 57.112% |
| MEDINET Co., Ltd. | 2.3 Million JPY | -41859.254% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.47 Billion JPY | 60.838% |
| AnGes, Inc. | 362.67 Million JPY | -166.906% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | -805.951% |
| Nxera Pharma Co., Ltd. | 73.97 Billion JPY | 98.691% |
| Immuno-Biological Laboratories Co., Ltd. | 235.98 Million JPY | -310.201% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | 12.708% |
| Carna Biosciences, Inc. | 182.97 Million JPY | -429.046% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 885.12 Million JPY | -9.363% |
| RaQualia Pharma Inc. | 367.71 Million JPY | -163.245% |
| Chiome Bioscience Inc. | 291 Million JPY | -232.646% |
| Kidswell Bio Corporation | 2.57 Billion JPY | 62.408% |
| PeptiDream Inc. | 22.79 Billion JPY | 95.754% |
| Oncolys BioPharma Inc. | 315.17 Million JPY | -207.136% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | 665 Million JPY | -45.564% |
| Healios K.K. | 4.53 Billion JPY | 78.641% |
| BrightPath Biotherapeutics Co., Ltd. | 112.5 Million JPY | -760.444% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 142.85 Million JPY | -577.62% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 97.54 Million JPY | -892.393% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 933.3 Million JPY | -3.718% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 723.93 Million JPY | -33.714% |
| StemCell Institute Inc. | 8.78 Million JPY | -10920.036% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 151.25 Million JPY | -540.0% |